Thirty-year trends in outcomes of percutaneous coronary interventions in diabetic patients.

[1]  K. Kent,et al.  Outcomes in diabetic versus nondiabetic patients who present with acute myocardial infarction and are treated with drug-eluting stents. , 2010, The American journal of cardiology.

[2]  Maria Mori Brooks,et al.  A randomized trial of therapies for type 2 diabetes and coronary artery disease. , 2009, The New England journal of medicine.

[3]  J. Spertus,et al.  Trends in the Association Between Age and In-Hospital Mortality After Percutaneous Coronary Intervention: National Cardiovascular Data Registry Experience , 2009, Circulation. Cardiovascular interventions.

[4]  R. M. Cooke,et al.  Two-Year Clinical Outcomes With Drug-Eluting Stents for Diabetic Patients With De Novo Coronary Lesions: Results From a Real-World Multicenter Registry , 2008, Circulation.

[5]  O. Pedersen,et al.  Effect of a multifactorial intervention on mortality in type 2 diabetes. , 2008, The New England journal of medicine.

[6]  V. Fuster,et al.  Design of the Future REvascularization Evaluation in patients with Diabetes mellitus: Optimal management of Multivessel disease (FREEDOM) Trial. , 2008, American heart journal.

[7]  J. Spertus,et al.  Comorbid conditions and outcomes after percutaneous coronary intervention , 2007, Heart.

[8]  B. Gersh,et al.  Twenty-Five–Year Trends in In-Hospital and Long-Term Outcome After Percutaneous Coronary Intervention: A Single-Institution Experience , 2007, Circulation.

[9]  J. Spertus,et al.  Bedside estimation of risk from percutaneous coronary intervention: the new Mayo Clinic risk scores. , 2007, Mayo Clinic proceedings.

[10]  H. Wiste,et al.  Trends in outcomes after percutaneous coronary intervention for chronic total occlusions: a 25-year experience from the Mayo Clinic. , 2007, Journal of the American College of Cardiology.

[11]  D. Holmes,et al.  Application of evidence-based medical therapy is associated with improved outcomes after percutaneous coronary intervention and is a valid quality indicator. , 2005, Journal of the American College of Cardiology.

[12]  John H Fuller,et al.  Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial , 2004, The Lancet.

[13]  R. Frye,et al.  Comparison of survival after successful percutaneous coronary intervention of patients with diabetes mellitus receiving insulin versus those receiving only diet and/or oral hypoglycemic agents. , 2004, American Journal of Cardiology.

[14]  B. Davis,et al.  Outcomes in Patients With Diabetes Mellitus Undergoing Percutaneous Coronary Intervention in the Current Era: A Report From the Prevention of REStenosis with Tranilast and its Outcomes (PRESTO) Trial , 2004, Circulation.

[15]  R. Frye,et al.  Burgeoning dilemmas in the management of diabetes and cardiovascular disease: rationale for the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) Trial. , 2003, Circulation.

[16]  Oluf Pedersen,et al.  Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. , 2003, The New England journal of medicine.

[17]  Mandeep Singh,et al.  Scores for Post–Myocardial Infarction Risk Stratification in the Community , 2002, Circulation.

[18]  M. Bell,et al.  Correlates of procedural complicationsand a simple integer risk scorefor percutaneous coronary intervention , 2002 .

[19]  D. Holmes,et al.  Does the presence of thrombus seen on a coronary angiogram affect the outcome after percutaneous coronary angioplasty? An Angiographic Trials Pool data experience. , 2001, Journal of the American College of Cardiology.

[20]  M. Bell,et al.  Improving outcome over time of percutaneous coronary interventions in unstable angina. , 2000, Journal of the American College of Cardiology.

[21]  M. Bell,et al.  Effect of age on the outcome of angioplasty for acute myocardial infarction among patients treated at the Mayo Clinic. , 2000, The American journal of medicine.

[22]  R. Kuntz.  Importance of considering atherosclerosis progression when choosing a coronary revascularization strategy: the diabetes-percutaneous transluminal coronary angioplasty dilemma. , 1999, Circulation.

[23]  B. Sobel,et al.  Increased plasminogen activator inhibitor type 1 in coronary artery atherectomy specimens from type 2 diabetic compared with nondiabetic patients: a potential factor predisposing to thrombosis and its persistence. , 1998, Circulation.